Relative effectiveness and safety of pharmacotherapeutic agents for patent ductus arteriosus (PDA) in preterm infants: a protocol for a multicentre comparative effectiveness study (CANRxPDA)

Autor: Jon Dorling, Souvik Mitra, Ruben Alvaro, Jaideep Kanungo, Christine Drolet, Nadya Ben Fadel, Prakesh Shah, Xiang Y Ye, Amish Jain, Faiza Khurshid, Joseph Y. Ting, Miroslav Stavel, Ayman Abou Mehrem, Amuchou Soraisham, Bonny Jasani, Deepak Louis, Anie Lapointe, Abbas Hyderi, Kumar Kumaran, Jaya Bodani, Dany Weisz, Mohammed Adie, Alyssa Morin, Soume Bhattacharya, Rody Canning, Tara Hatfield, Courtney E Gardner
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: BMJ Open, Vol 11, Iss 5 (2021)
Druh dokumentu: article
ISSN: 2044-6055
DOI: 10.1136/bmjopen-2021-050682
Popis: Introduction Patent ductus arteriosus (PDA) is the most common cardiovascular problem that develops in preterm infants and evidence regarding the best treatment approach is lacking. Currently available medical options to treat a PDA include indomethacin, ibuprofen or acetaminophen. Wide variation exists in PDA treatment practices across Canada. In view of this large practice variation across Canadian neonatal intensive care units (NICUs), we plan to conduct a comparative effectiveness study of the different pharmacotherapeutic agents used to treat the PDA in preterm infants.Methods and analysis A multicentre prospective observational comparative-effectiveness research study of extremely preterm infants born
Databáze: Directory of Open Access Journals